Abstract:Evidence from our laboratory has established a role for the G0/G1 Switch Gene 2 (G0S2) as the primary inhibitor of adipose lipolysis through inhibition of adipose triglyceride lipase (ATGL), the rate‐limiting enzyme in triglyceride hydrolysis. We have demonstrated that differential expression of G0S2 plays a crucial role in regulating hepatic lipid content during fasting and feeding. Hepatic G0S2 expression is also significantly increased in a pathological condition in mice with obesity‐induced hepatic steatosis or non‐alcoholic fatty liver disease (NAFLD), major metabolic health issues in today's society. Based on preliminary evidence we hypothesized there is a dynamic relationship between adipose lipolysis and hepatic G0S2 expression during physiological fasting, a relationship that has not been previously described. To better understand this relationship we evaluated the effect of free fatty acids (FFA) on G0S2 expression in liver. Interestingly, hepatic G0S2 expression during fasting results from increased free fatty acid (FFA) delivery to the liver from adipose tissue. Moreover, we identified that increases in hepatic FFA lead to increased G0S2 expression in a bi‐mechanistic manner. We investigated and subsequently determined that both transcriptional activation of G0S2 and inhibition of protein degradation are occurring in response to increased hepatic FFA levels. Utilizing a luciferase based reporter system and in vivo chromatin immunoprecipitation we found transcriptional activation of G0S2 in liver occurs in response to activation of liver‐X‐receptor α (LXRα). LXRα is a known regulator of pro‐lipogenic signaling in liver and plays a major role in cholesterol homeostasis. It has also been shown that LXRα can be activated in response to FAs most likely through its dimerization partner RXRα that is a known FA responsive transcription factor. We demonstrate G0S2 is a direct downstream target gene for LXRα. Additionally, the direct repeat 4 (DR4) LXR response element (LXRE) found 2kb upstream of the transcriptional start site in the G0S2 promoter is required for G0S2/ LXRα binding. This DR4 binding site is conserved between the human and mouse isoforms of G0S2 and is required in each for LXRα binding. Furthermore, we found that G0S2 is subject to ubiquitin modification and is degraded in a proteasome dependent pathway. Mutation analysis of the six‐lysine residues found in G0S2 provided key evidence that the lysine at position 25 is the prominent site for ubiquitylation. The G0S2 K25 mutant is more stable than wild‐type G0S2, which is consistent with the accompanying decrease in ubiquitylation. Additionally, fatty acids were able to abrogate G0S2 degradation and increase protein stability. These findings indicate that two mechanisms of expression regulation in combination with adipose lipolysis are functioning concomitantly to regulate hepatic G0S2 expression under physiological conditions. Additionally, aberrant G0S2 expression may contribute to the pathological setting with metabolically linked diseases including NAFLD. Support or Funding Information This work was supported by NIDDK grants DK089178 and 2R56DK089178 from the National Institutes of Health. Pre‐doctoral funding support for B.H. was generously provided by the Mayo Graduate School and Mayo Foundation for Medical Education & Research.

“New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Inactivation of Hypothalamic FAS Protects Mice from Diet-Induced Obesity and Inflammation

Brain Fatty Acid Synthase Activates PPARalpha to Maintain Energy Homeostasis.

Acyl‐CoA Thioesterase 1 regulates hepatic lipid metabolism and PPAR‐α signaling

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Hepatic CPT1A Facilitates Liver–Adipose Cross Talk via Induction of FGF21 in Mice

Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice

Fat-1 Mice Prevent High-Fat Plus High-Sugar Diet-Induced Non-Alcoholic Fatty Liver Disease

Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice

Activation of Liver X Receptor Regulates Fatty Acid Synthase Expression in Diabetic Liver

41 Cholesterol 7Α-Hydroxylase (CYP7A1) Mediates Resistance to High-Fat Diet-Induced Obesity and Diabetes Through Elevated Tauro-β-Muricholic Acid and Inhibition of Farnesoid X Receptor Signaling in the Intestine

Multifaceted regulation of hepatic G0/G1 Switch Gene 2 expression and relevance to lipid metabolism

Hepatocyte-secreted FAM3D Ameliorates Hepatic Steatosis by Activating FPR1-hnRNP U-GR-SCAD Pathway to Enhance Lipid Oxidation

Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a

Hepatocyte-Specific PEX16 Abrogation in Mice Leads to Hepatocyte Proliferation, Alteration of Hepatic Lipid Metabolism, and Resistance to High-Fat Diet (HFD)-Induced Hepatic Steatosis and Obesity

Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice

Hepatic Sirtuin 1 is Dispensable for Fibrate-Induced Peroxisome Proliferator-Activated Receptor-Α Function in Vivo.

Liver ACOX1 regulates levels of circulating lipids that promote metabolic health through adipose remodeling

Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL/6J mice